Dr. Schwartz was Chief Medical Officer at ArQule from 2008, and also Head of Research & Development from 2013, until the company’s acquisition by Merck in 2020 for $2.7 billion. Dr. Schwartz has extensive experience in the pharmaceutical and biotechnology industries. Prior to joining ArQule, he was Chief Medical Officer and Senior Vice President, Clinical and Regulatory Affairs, at Ziopharm Oncology where he built and led the clinical, regulatory, and quality assurance departments with responsibilities for the development of new cancer drugs. Prior to Ziopharm, Dr. Schwartz held a number of leadership positions at Bayer Healthcare. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib (Nexavar®) and led the clinical team through a successful Phase 3 trial in renal cell cancer, leading to U.S. Food and Drug Administration (FDA) approval. He has extensive regulatory experience working with the FDA’s Oncology Division, the European Medicines Agency (EMA), and numerous other health authorities. Dr. Schwartz has been involved in multiple clinical and regulatory activities, including Phase 4 studies and interactions with the National Cancer Institute and other oncology cooperative groups. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in industry. Dr. Schwartz serves on the Boards of Mereo Pharma Group Plc, LifeSci Acquisition Corp and Enlivex Therapeutics Ltd. He is also an advisor to the California Institute of Regenerative Medicine and Pontifax Venture Capital.